Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries

Zazuli, Zulfan; Hoog, Catharina J P Op 't; Vijverberg, Susanne; Masereeuw, Rosalinde; Rassekh, Shahrad R.; Medeiros, Mara; Rivas-Ruíz, Rodolfo; Zee, Anke H. Maitland‐van der; Carleton, Bruce

doi:10.1007/s00467-022-05632-z

Cited by 5 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adult patients, the incidence of cisplatin-induced hypomagnesemia is reported to be as high as 90% [ 69 ]. Sustained excretion rates also apply for amphotericin B; other nephrotoxic agents include loop and thiazide diuretics, aminoglycosides, and cyclosporine [ 70 , 71 , 72 , 73 ].…”

Section: Micronutrientsmentioning

confidence: 99%

Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts

et al. 2023

View full text Add to dashboard Cite

Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence. Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “dietary supplements”, “vitamins”, “micronutrients”, “calcium”, “magnesium”, “vitamin D”, “zinc” “glutamine”, “selen”, and “omega-3 fatty acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention. Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).

show abstract

Section: Micronutrientsmentioning

confidence: 99%

Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Cisplatin is a widely used anti-solid tumor drug that can target a variety of cancers including those of the breast, ovary, lung, testis, head, and neck [ 1 , 2 , 3 , 4 , 5 ]. However, cisplatin’s clinical application and efficacy is highly limited due to its severe adverse effects, in particular, its nephrotoxicity [ 6 , 7 , 8 , 9 , 10 , 11 ]. It has been estimated that nearly 30% of cancer patients receiving cisplatin treatment could exhibit acute kidney injury (AKI) after the ingestion of a single high dose of cisplatin [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Cisplatin-Induced Kidney Toxicity: Potential Roles of Major NAD+-Dependent Enzymes and Plant-Derived Natural Products

Iskander

2022

Biomolecules

View full text Add to dashboard Cite

Cisplatin is an FDA approved anti-cancer drug that is widely used for the treatment of a variety of solid tumors. However, the severe adverse effects of cisplatin, particularly kidney toxicity, restrict its clinical and medication applications. The major mechanisms of cisplatin-induced renal toxicity involve oxidative stress, inflammation, and renal fibrosis, which are covered in this short review. In particular, we review the underlying mechanisms of cisplatin kidney injury in the context of NAD+-dependent redox enzymes including mitochondrial complex I, NAD kinase, CD38, sirtuins, poly-ADP ribosylase polymerase, and nicotinamide nucleotide transhydrogenase (NNT) and their potential contributing roles in the amelioration of cisplatin-induced kidney injury conferred by natural products derived from plants. We also cover general procedures used to create animal models of cisplatin-induced kidney injury involving mice and rats. We highlight the fact that more studies will be needed to dissect the role of each NAD+-dependent redox enzyme and its involvement in modulating cisplatin-induced kidney injury, in conjunction with intensive research in NAD+ redox biology and the protective effects of natural products against cisplatin-induced kidney injury.

show abstract

“…Therefore, we recommend regular monitoring of selected laboratory tests, including total serum protein, albumin, glucose, and electrolytes. Their concentration can be changed not only by the poor nutritional status, but also by the cancer itself and its intensive treatment [23,24]. Chemotherapy and antifungal treatment can cause significant electrolyte disturbances, due to the nephrotoxicity of the drugs used or gastrointestinal loses [23,24].…”

mentioning

confidence: 99%

“…Their concentration can be changed not only by the poor nutritional status, but also by the cancer itself and its intensive treatment [23,24]. Chemotherapy and antifungal treatment can cause significant electrolyte disturbances, due to the nephrotoxicity of the drugs used or gastrointestinal loses [23,24]. In malnourished patients, an increase in albumin and total protein concentrations may be the indicators of the effectiveness of nutritional intervention [25].…”

mentioning

confidence: 99%

Managing Undernutrition in Pediatric Oncology: A Consensus Statement Developed Using the Delphi Method by the Polish Society for Clinical Nutrition of Children and the Polish Society of Pediatric Oncology and Hematology

Budka-Chrzęszczyk,

Szlagatys-Sidorkiewicz,

Bień

et al. 2024

Nutrients

View full text Add to dashboard Cite

“Managing Undernutrition in Pediatric Oncology” is a collaborative consensus statement of the Polish Society for Clinical Nutrition of Children and the Polish Society of Pediatric Oncology and Hematology. The early identification and accurate management of malnutrition in children receiving anticancer treatment are crucial components to integrate into comprehensive medical care. Given the scarcity of high-quality literature on this topic, a consensus statement process was chosen over other approaches, such as guidelines, to provide comprehensive recommendations. Nevertheless, an extensive literature review using the PubMed database was conducted. The following terms, namely pediatric, childhood, cancer, pediatric oncology, malnutrition, undernutrition, refeeding syndrome, nutritional support, and nutrition, were used. The consensus was reached through the Delphi method. Comprehensive recommendations aim to identify malnutrition early in children with cancer and optimize nutritional interventions in this group. The statement underscores the importance of baseline and ongoing assessments of nutritional status and the identification of the risk factors for malnutrition development, and it presents tools that can be used to achieve these goals. This consensus statement establishes a standardized approach to nutritional support, aiming to optimize outcomes in pediatric cancer patients.

show abstract

Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries

Cited by 5 publications

References 42 publications

Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts

Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts

Cisplatin-Induced Kidney Toxicity: Potential Roles of Major NAD+-Dependent Enzymes and Plant-Derived Natural Products

Managing Undernutrition in Pediatric Oncology: A Consensus Statement Developed Using the Delphi Method by the Polish Society for Clinical Nutrition of Children and the Polish Society of Pediatric Oncology and Hematology

Contact Info

Product

Resources

About